



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
February 2026





FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV ("PLWH"), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC's Ministry of Health, through the province's PharmaCare Program, the BC-CfE's Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE's Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE's mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC's health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report's date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS





ACKNOWLEDGEMENTS

The BC-CfE Drug Treatment Programs acknowledge with thanks the support provided by the BC-CfE Drug Treatment Programs staff, program participants, and St. Paul's Hospital Ambulatory Pharmacy.

Prepared by:

Dr. Julio S.G. Montaner, MD, FRCPC
Executive Director and Physician in Chief
BC Centre for Excellence in HIV/AIDS

Dr. Junine Toy, PharmD
Director, Drug Treatment Programs
BC Centre for Excellence in HIV/AIDS

Dr. Chanson Brumme, PhD
Assistant Director, Research Laboratories
BC Centre for Excellence in HIV/AIDS

Raja Dutta
Oracle Programmer and Database Developer
BC Centre for Excellence in HIV/AIDS

Shinta Thio, MSc
Research Coordinator
BC Centre for Excellence in HIV/AIDS

Paul Sereda
Data Management Lead
BC Centre for Excellence in HIV/AIDS

Dr. Sandra Chang, PharmD
Clinical Pharmacy Specialist, Quality Assurance and
Pharmacovigilance Initiative
BC Centre for Excellence in HIV/AIDS

Jelena Antic, Quality Assurance (Technical), Drug
Treatment Programs
BC Centre for Excellence in HIV/AIDS

Cameron Collins
Communications Specialist

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC's PharmaCare and Ministry of Health.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.





TABLE OF CONTENTS

1. HIV Treatment Program Participants - Figures and Tables

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category (graph)
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category (table)
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Participants by CD4 Count
- 1.17 Distribution of Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 Count for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 Count for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. HIV Treatment Program Participants - Additional Tables

- 2.1 Participants by Year of HIV Treatment Program Initiation (1987 - 2026)
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. HIV Treatment Program Participants by Health Authority

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority
- 3.3 Fraser Health Authority
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority
- 3.6 Northern Health Authority





TABLE OF CONTENTS (continued)


4. Participant Demographics by Health Authority

- 4.1 Demographic Profile of Program Participants
- 4.2 Demographic Profile of Program Participants in INTERIOR Health Authority
- 4.3 Distribution of Participants by Program Duration in INTERIOR Health Authority
- 4.4 Demographic Profile of Program Participants in FRASER Health Authority
- 4.5 Distribution of Participants by Program Duration in FRASER Health Authority
- 4.6 Demographic Profile of Program Participants in VANCOUVER COASTAL Health Authority
- 4.7 Distribution of Participants by Program Duration in VANCOUVER COASTAL Health Authority
- 4.8 Demographic Profile of Program Participants in VANCOUVER ISLAND Health Authority
- 4.9 Distribution of Participants by Program Duration in VANCOUVER ISLAND Health Authority
- 4.10 Demographic Profile of Program Participants in NORTHERN Health Authority
- 4.11 Distribution of Participants by Program Duration in NORTHERN Health Authority
- 4.12 Demographic Profile of Program Participants with Clinician-reported Indigenous Status



1.1
Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
February 2026

N = 7789




Health Authority	All	Median Age (Q1, Q3)	----- Gender Identity -----		
			Cis-men	Cis-women	Gender Diverse
INTERIOR	626	56 (44, 64)	493	126	7
FRASER	2184	53 (41, 62)	1643	517	24
VANCOUVER COASTAL	3641	57 (44, 64)	3140	448	53
VANCOUVER ISLAND	1082	58 (46, 65)	890	183	9
NORTHERN	251	54 (44, 63)	167	82	<5
Total Health Authority:	7789	56 (44, 64)	6336	1358	95

On antiretroviral treatment: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.
Total Health Authority also includes participants with unknown residence (not shown).
Gender Identity as reported by clinician.
Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
February 2021 - February 2026




1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

MON-YYYY	Total Participants	INSTI		Boosted PI		NNRTI		2 drugs from		≥3 drugs from		Other	
		2 N(t)RTIs	%	2 N(t)RTIs	%	2 N(t)RTIs	%	2 classes	%	≥3 classes	%	n	%
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	619	8.1	57	0.7
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1001	13.1	621	8.1	56	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1024	13.3	607	7.9	52	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1034	13.5	607	7.9	54	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1061	13.7	606	7.9	52	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1082	14.0	603	7.8	49	0.6
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1125	14.6	596	7.7	51	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1169	15.1	594	7.7	45	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1177	15.3	582	7.6	44	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1200	15.5	589	7.6	47	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1235	16.0	587	7.6	43	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1265	16.4	578	7.5	45	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1292	16.8	573	7.5	42	0.5
APR-2025	7719	4947	64.1	394	5.1	432	5.6	1321	17.1	585	7.6	40	0.5
MAY-2025	7705	4911	63.7	386	5.0	423	5.5	1370	17.8	574	7.4	41	0.5
JUN-2025	7713	4893	63.4	371	4.8	417	5.4	1428	18.5	566	7.3	38	0.5
JUL-2025	7772	4940	63.6	359	4.6	411	5.3	1460	18.8	565	7.3	37	0.5
AUG-2025	7761	4920	63.4	346	4.5	407	5.2	1482	19.1	566	7.3	40	0.5
SEP-2025	7736	4897	63.3	334	4.3	392	5.1	1508	19.5	567	7.3	38	0.5
OCT-2025	7774	4920	63.3	331	4.3	384	4.9	1533	19.7	569	7.3	37	0.5
NOV-2025	7789	4927	63.3	325	4.2	380	4.9	1552	19.9	567	7.3	38	0.5
DEC-2025	7833	4965	63.4	321	4.1	371	4.7	1567	20.0	573	7.3	36	0.5
JAN-2026	7808	4940	63.3	309	4.0	374	4.8	1587	20.3	564	7.2	34	0.4
FEB-2026	7789	4912	63.1	294	3.8	370	4.8	1616	20.7	563	7.2	34	0.4

Total Participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.
n: number of participants on the specified regimen category in the specified month.
%: ratio of n and total participants on antiretroviral treatment in the specified month.
INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,
N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor.



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
February 2021 - February 2026



1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT													
MON-YYYY	Total	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
MAR-2024	7493	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	7525	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	7544	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	7544	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	7570	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	7563	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	7551	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	7577	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	7555	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	7572	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	7591	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	7547	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	7537	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1
APR-2025	7557	1304	17.3	4909	65.0	2664	35.3	4374	57.9	655	8.7	6	0.1
MAY-2025	7537	1242	16.5	4894	64.9	2654	35.2	4373	58.0	630	8.4	7	0.1
JUN-2025	7540	1196	15.9	4910	65.1	2647	35.1	4406	58.4	620	8.2	7	0.1
JUL-2025	7593	1137	15.0	4981	65.6	2629	34.6	4482	59.0	615	8.1	7	0.1
AUG-2025	7578	1076	14.2	4992	65.9	2596	34.3	4511	59.5	594	7.8	7	0.1
SEP-2025	7555	1043	13.8	4989	66.0	2576	34.1	4527	59.9	571	7.6	7	0.1
OCT-2025	7583	998	13.2	5038	66.4	2557	33.7	4581	60.4	560	7.4	7	0.1
NOV-2025	7597	958	12.6	5068	66.7	2542	33.5	4627	60.9	550	7.2	7	0.1
DEC-2025	7635	930	12.2	5130	67.2	2527	33.1	4693	61.5	544	7.1	7	0.1
JAN-2026	7604	898	11.8	5121	67.4	2502	32.9	4698	61.8	522	6.9	6	0.1
FEB-2026	7580	862	11.4	5110	67.4	2487	32.8	4696	62.0	516	6.8	5	0.1


Total: number of participants whose treatment regimen contains the given antiretroviral class in BC program in the specified month.

n: number of participants on antiretroviral treatment whose regimen contains the specified medication in the given antiretroviral class.

%: ratio of n and total participants whose treatment contains the given antiretroviral drug class.



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
February 2021 - February 2026




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

MON-YYYY	Total	atazanavir		darunavir		lopinavir	
		n	%	n	%	n	%
MAR-2024	1094	225	20.6	840	76.8	30	2.7
APR-2024	1088	224	20.6	835	76.8	31	2.9
MAY-2024	1081	221	20.4	828	76.6	33	3.1
JUN-2024	1059	214	20.2	813	76.8	33	3.1
JUL-2024	1052	216	20.5	805	76.5	33	3.1
AUG-2024	1021	208	20.4	784	76.8	31	3.0
SEP-2024	1001	203	20.3	772	77.1	27	2.7
OCT-2024	977	197	20.2	754	77.2	27	2.8
NOV-2024	957	190	19.9	742	77.5	28	2.9
DEC-2024	947	184	19.4	738	77.9	26	2.8
JAN-2025	922	177	19.2	726	78.7	23	2.5
FEB-2025	891	168	18.9	700	78.6	24	2.7
MAR-2025	875	167	19.1	686	78.4	24	2.7
APR-2025	860	153	17.8	684	79.5	24	2.8
MAY-2025	840	151	18.0	666	79.3	24	2.9
JUN-2025	823	150	18.2	652	79.2	23	2.8
JUL-2025	806	146	18.1	639	79.3	23	2.9
AUG-2025	788	142	18.0	624	79.2	23	2.9
SEP-2025	768	140	18.2	607	79.0	22	2.9
OCT-2025	755	137	18.2	599	79.3	20	2.7
NOV-2025	749	135	18.0	596	79.6	20	2.7
DEC-2025	748	130	17.4	599	80.1	20	2.7
JAN-2026	717	124	17.3	575	80.2	19	2.7
FEB-2026	694	122	17.6	556	80.1	18	2.6

Total: number of participants whose treatment regimen contains the given antiretroviral class in BC program in the specified month.
n: number of participants on antiretroviral treatment whose regimen contains the specified medication in the given antiretroviral class.
%: ratio of n and total participants whose treatment contains the given antiretroviral drug class.



1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
February 2021 - February 2026



**1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT**


MON-YYYY	Total	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0
APR-2025	818	317 38.8	137 16.8	61 7.5	128 15.7	177 21.6
MAY-2025	809	313 38.7	129 16.0	60 7.4	126 15.6	181 22.4
JUN-2025	812	315 38.8	127 15.6	60 7.4	122 15.0	190 23.4
JUL-2025	809	322 39.8	124 15.3	56 6.9	113 14.0	194 24.0
AUG-2025	805	329 40.9	117 14.5	57 7.1	109 13.5	198 24.6
SEP-2025	806	335 41.6	116 14.4	52 6.5	107 13.3	199 24.7
OCT-2025	808	344 42.6	113 14.0	53 6.6	101 12.5	199 24.6
NOV-2025	803	343 42.7	109 13.6	50 6.2	99 12.3	204 25.4
DEC-2025	805	352 43.7	108 13.4	50 6.2	91 11.3	209 26.0
JAN-2026	819	361 44.1	103 12.6	52 6.4	87 10.6	218 26.6
FEB-2026	822	365 44.4	100 12.2	49 6.0	83 10.1	226 27.5

Total: number of participants whose treatment regimen contains the given antiretroviral class in BC program in the specified month.
n: number of participants on antiretroviral treatment whose regimen contains the specified medication in the given antiretroviral class.
%: ratio of n and total participants whose treatment contains the given antiretroviral drug class.





1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
February 2021 - February 2026





1.11 Number of Participants on Integrase Inhibitors by INGREDIENT


MON-YYYY	Total	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
MAR-2024	6435	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	6483	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	6511	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	6528	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	6584	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	6593	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	6610	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	6680	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	6681	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	6720	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	6762	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	6754	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	6767	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6
APR-2025	6834	3985 58.3	49 0.7	2488 36.4	176 2.6	167 2.4
MAY-2025	6840	3987 58.3	57 0.8	2478 36.2	174 2.5	165 2.4
JUN-2025	6868	4021 58.6	67 1.0	2483 36.2	170 2.5	162 2.4
JUL-2025	6952	4102 59.0	75 1.1	2478 35.6	168 2.4	159 2.3
AUG-2025	6954	4132 59.4	81 1.2	2453 35.3	162 2.3	159 2.3
SEP-2025	6956	4150 59.7	92 1.3	2435 35.0	157 2.3	152 2.2
OCT-2025	7013	4204 60.0	98 1.4	2423 34.6	159 2.3	147 2.1
NOV-2025	7035	4237 60.2	104 1.5	2417 34.4	159 2.3	141 2.0
DEC-2025	7089	4303 60.7	109 1.5	2408 34.0	160 2.3	136 1.9
JAN-2026	7082	4314 60.9	119 1.7	2391 33.8	154 2.2	137 1.9
FEB-2026	7079	4320 61.0	126 1.8	2388 33.7	146 2.1	131 1.9

Total: number of participants whose treatment regimen contains the given antiretroviral class in BC program in the specified month.
n: number of participants on antiretroviral treatment whose regimen contains the specified medication in the given antiretroviral class.
%: ratio of n and total participants whose treatment contains the given antiretroviral drug class.





1.12 Distribution of Participants on other Antiretroviral Drug Classes by INGREDIENT
February 2021 - February 2026





1.13 Number of Participants on other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5
APR-2025	19	2	10.5	15	79.0	2	10.5
MAY-2025	17	2	11.8	14	82.4	1	5.9
JUN-2025	19	2	10.5	15	79.0	2	10.5
JUL-2025	22	2	9.1	16	72.7	4	18.2
AUG-2025	24	2	8.3	16	66.7	6	25.0
SEP-2025	25	2	8.0	15	60.0	8	32.0
OCT-2025	23	2	8.7	11	47.8	10	43.5
NOV-2025	26	2	7.7	13	50.0	11	42.3
DEC-2025	27	2	7.4	14	51.9	11	40.7
JAN-2026	28	2	7.1	14	50.0	12	42.9
FEB-2026	30	2	6.7	14	46.7	14	46.7

Total: number of participants whose treatment regimen contains an other antiretroviral drug class in BC program in the specified month.

n: number of participants on antiretroviral treatment which contains the specified medication in an other antiretroviral drug class.


%: ratio of n and total participants whose treatment contains an other antiretroviral drug class.

Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary.





1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
February 2021 - February 2026





1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

MON-YYYY	Total Participants	2 or fewer drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%
MAR-2024	7636	993	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	7670	1003	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	7687	1026	13.4	6188	80.5	434	5.7	39	0.5
JUN-2024	7687	1035	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	7718	1063	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	7709	1084	14.1	6155	79.8	431	5.6	39	0.5
SEP-2024	7697	1127	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	7725	1170	15.2	6087	78.8	427	5.5	41	0.5
NOV-2024	7703	1178	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	7720	1202	15.6	6054	78.4	424	5.5	40	0.5
JAN-2025	7739	1237	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	7696	1267	16.5	5977	77.7	414	5.4	38	0.5
MAR-2025	7689	1296	16.9	5942	77.3	414	5.4	37	0.5
APR-2025	7719	1324	17.2	5939	76.9	419	5.4	37	0.5
MAY-2025	7705	1374	17.8	5882	76.3	410	5.3	39	0.5
JUN-2025	7713	1432	18.6	5845	75.8	396	5.1	40	0.5
JUL-2025	7772	1462	18.8	5874	75.6	399	5.1	37	0.5
AUG-2025	7761	1487	19.2	5838	75.2	396	5.1	40	0.5
SEP-2025	7736	1511	19.5	5790	74.8	398	5.1	37	0.5
OCT-2025	7774	1535	19.8	5805	74.7	395	5.1	39	0.5
NOV-2025	7789	1554	20.0	5802	74.5	393	5.1	40	0.5
DEC-2025	7833	1569	20.0	5833	74.5	393	5.0	38	0.5
JAN-2026	7808	1589	20.4	5799	74.3	382	4.9	38	0.5
FEB-2026	7789	1619	20.8	5745	73.8	389	5.0	36	0.5

Total Participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.
Number of drugs refers to the number of individual drugs in the antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting).


n: number of participants on the specified number of antiretroviral drugs in the specified month.

%: ratio of n and total participants on antiretroviral treatment in the specified month.





1.16 Percent Distribution of Participants by CD4 Count
February 2021 - February 2026




1.17 Distribution of Participants by CD4 Count

MON-YYYY	Total Participants	CD4 > 500 n %	CD4 350 - 500 n %	CD4 200 - 349 n %	CD4 < 200 n %	CD4: Unreported n %
MAR-2024	7636	3649 47.8	924 12.1	498 6.5	255 3.3	2310 30.3
APR-2024	7670	3627 47.3	944 12.3	486 6.3	253 3.3	2360 30.8
MAY-2024	7687	3661 47.6	923 12.0	486 6.3	248 3.2	2369 30.8
JUN-2024	7687	3680 47.9	886 11.5	493 6.4	247 3.2	2381 31.0
JUL-2024	7718	3682 47.7	912 11.8	493 6.4	248 3.2	2383 30.9
AUG-2024	7709	3660 47.5	910 11.8	491 6.4	251 3.3	2397 31.1
SEP-2024	7697	3639 47.3	935 12.2	489 6.4	241 3.1	2393 31.1
OCT-2024	7725	3624 46.9	948 12.3	499 6.5	243 3.2	2411 31.2
NOV-2024	7703	3652 47.4	917 11.9	505 6.6	234 3.0	2395 31.1
DEC-2024	7720	3658 47.4	928 12.0	508 6.6	232 3.0	2394 31.0
JAN-2025	7739	3650 47.2	939 12.1	509 6.6	233 3.0	2408 31.1
FEB-2025	7696	3640 47.3	930 12.1	511 6.6	223 2.9	2392 31.1
MAR-2025	7689	3620 47.1	934 12.2	508 6.6	225 2.9	2402 31.2
APR-2025	7719	3667 47.5	902 11.7	500 6.5	230 3.0	2420 31.4
MAY-2025	7705	3655 47.4	875 11.4	493 6.4	229 3.0	2453 31.8
JUN-2025	7713	3656 47.4	899 11.7	477 6.2	223 2.9	2458 31.9
JUL-2025	7772	3697 47.6	884 11.4	510 6.6	215 2.8	2466 31.7
AUG-2025	7761	3714 47.9	878 11.3	504 6.5	217 2.8	2448 31.5
SEP-2025	7736	3718 48.1	870 11.3	493 6.4	221 2.9	2434 31.5
OCT-2025	7774	3760 48.4	872 11.2	494 6.4	203 2.6	2445 31.5
NOV-2025	7789	3753 48.2	881 11.3	488 6.3	211 2.7	2456 31.5
DEC-2025	7833	3770 48.1	891 11.4	491 6.3	211 2.7	2470 31.5
JAN-2026	7808	3793 48.6	873 11.2	498 6.4	201 2.6	2443 31.3
FEB-2026	7789	3799 48.8	862 11.1	497 6.4	213 2.7	2418 31.0

CD4 value (cells/μL) as per the most recent test within the past 12 months.
CD4 Unreported: CD4 not tested or reported within the past 12 months.
Total Participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.
n: number of participants with the specified CD4 range.
%: ratio of n and total participants on antiretroviral treatment.



1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment
February 2021 - February 2026




1.19
Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from		≥3 drugs from		Other	
		2 N(t)RTIs	%	2 N(t)RTIs	%	2 N(t)RTIs	%	2 classes	%	≥3 classes	%	n	%
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
APR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAY-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUL-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2025	13	12	92.3	0	0.0	0	0.0	1	7.7	0	0.0	0	0.0
OCT-2025	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2025	19	17	89.5	0	0.0	0	0.0	2	10.5	0	0.0	0	0.0
DEC-2025	3	3	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2026	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2026	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
Total: number of participants initiating antiretroviral treatment in BC program in the specified month.
n: number of participants on the specified regimen category in the specified month.
%: ratio of n and total number of participants initiating antiretroviral treatment in the specified month.



1.20 Pre-entry CD4 Count for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
February 2021 - February 2026



**1.21 Pre-entry CD4 Count for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program**

MON-YYYY	Total Naïve starts	CD4 > 500 n %	CD4 350 - 500 n %	CD4 200 - 349 n %	CD4 < 200 n %	CD4: Unreported n %
MAR-2024	13	4 30.8	1 7.7	1 7.7	5 38.5	2 15.4
APR-2024	20	9 45.0	1 5.0	6 30.0	4 20.0	0 0.0
MAY-2024	16	6 37.5	1 6.3	3 18.8	5 31.3	1 6.3
JUN-2024	23	7 30.4	4 17.4	10 43.5	2 8.7	0 0.0
JUL-2024	10	2 20.0	3 30.0	3 30.0	1 10.0	1 10.0
AUG-2024	15	3 20.0	3 20.0	4 26.7	5 33.3	0 0.0
SEP-2024	7	1 14.3	1 14.3	4 57.1	1 14.3	0 0.0
OCT-2024	15	3 20.0	3 20.0	3 20.0	6 40.0	0 0.0
NOV-2024	9	1 11.1	2 22.2	3 33.3	3 33.3	0 0.0
DEC-2024	10	2 20.0	2 20.0	2 20.0	4 40.0	0 0.0
JAN-2025	14	1 7.1	5 35.7	2 14.3	6 42.9	0 0.0
FEB-2025	9	3 33.3	3 33.3	1 11.1	2 22.2	0 0.0
MAR-2025	12	2 16.7	2 16.7	2 16.7	5 41.7	1 8.3
APR-2025	12	4 33.3	2 16.7	2 16.7	3 25.0	1 8.3
MAY-2025	17	2 11.8	5 29.4	3 17.7	6 35.3	1 5.9
JUN-2025	8	1 12.5	2 25.0	3 37.5	2 25.0	0 0.0
JUL-2025	8	2 25.0	2 25.0	2 25.0	0 0.0	2 25.0
AUG-2025	17	5 29.4	6 35.3	1 5.9	3 17.7	2 11.8
SEP-2025	13	3 23.1	4 30.8	0 0.0	5 38.5	1 7.7
OCT-2025	10	2 20.0	3 30.0	1 10.0	3 30.0	1 10.0
NOV-2025	19	8 42.1	7 36.8	2 10.5	1 5.3	1 5.3
DEC-2025	3	2 66.7	0 0.0	0 0.0	1 33.3	0 0.0
JAN-2026	9	2 22.2	3 33.3	1 11.1	3 33.3	0 0.0
FEB-2026	12	2 16.7	4 33.3	0 0.0	6 50.0	0 0.0


Total Naïve starts: number of participants initiating antiretroviral treatment in BC program in the specified month.

Pre-entry CD4 Count (cells/ μ L) refers to most recent CD4 test result before antiretroviral treatment initiation.





1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
February 2021 - February 2026





1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

			----- ARV Drug Class -----						
MON-YYYY	Total Participants	Any resistance n %	NNRTI n %	N(t)RTI n %	PI n %	INSTI n %	Never Tested n %		
MAR-2024	7636	2298 30.1	1298 17.0	1643 21.5	555 7.3	108 1.4	1222 16.0		
APR-2024	7670	2309 30.1	1306 17.0	1643 21.4	563 7.3	105 1.4	1231 16.1		
MAY-2024	7687	2313 30.1	1306 17.0	1642 21.4	569 7.4	105 1.4	1246 16.2		
JUN-2024	7687	2303 30.0	1309 17.0	1629 21.2	561 7.3	104 1.4	1256 16.3		
JUL-2024	7718	2316 30.0	1320 17.1	1643 21.3	560 7.3	110 1.4	1271 16.5		
AUG-2024	7709	2296 29.8	1310 17.0	1624 21.1	551 7.2	107 1.4	1280 16.6		
SEP-2024	7697	2294 29.8	1307 17.0	1629 21.2	555 7.2	104 1.4	1285 16.7		
OCT-2024	7725	2289 29.6	1289 16.7	1624 21.0	556 7.2	100 1.3	1293 16.7		
NOV-2024	7703	2277 29.6	1286 16.7	1620 21.0	548 7.1	98 1.3	1302 16.9		
DEC-2024	7720	2270 29.4	1282 16.6	1608 20.8	543 7.0	102 1.3	1320 17.1		
JAN-2025	7739	2260 29.2	1281 16.6	1600 20.7	531 6.9	106 1.4	1336 17.3		
FEB-2025	7696	2251 29.3	1274 16.6	1583 20.6	531 6.9	107 1.4	1343 17.5		
MAR-2025	7689	2242 29.2	1266 16.5	1568 20.4	533 6.9	109 1.4	1339 17.4		
APR-2025	7719	2242 29.1	1267 16.4	1578 20.4	527 6.8	105 1.4	1354 17.5		
MAY-2025	7705	2242 29.1	1272 16.5	1574 20.4	532 6.9	105 1.4	1351 17.5		
JUN-2025	7713	2232 28.9	1265 16.4	1560 20.2	522 6.8	106 1.4	1368 17.7		
JUL-2025	7772	2240 28.8	1272 16.4	1566 20.2	523 6.7	106 1.4	1390 17.9		
AUG-2025	7761	2242 28.9	1269 16.4	1569 20.2	524 6.8	108 1.4	1394 18.0		
SEP-2025	7736	2227 28.8	1257 16.3	1562 20.2	519 6.7	108 1.4	1408 18.2		
OCT-2025	7774	2231 28.7	1262 16.2	1564 20.1	516 6.6	107 1.4	1416 18.2		
NOV-2025	7789	2235 28.7	1264 16.2	1566 20.1	514 6.6	104 1.3	1421 18.2		
DEC-2025	7833	2227 28.4	1270 16.2	1559 19.9	515 6.6	109 1.4	1443 18.4		
JAN-2026	7808	2226 28.5	1257 16.1	1554 19.9	509 6.5	108 1.4	1450 18.6		
FEB-2026	7789	2230 28.6	1254 16.1	1558 20.0	511 6.6	110 1.4	1440 18.5		

Total participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.

Any resistance: number of participants on antiretroviral treatment with current or historic resistance to any drug within ≥ 1 antiretroviral drug class (based on cumulative tests in BC, until the specified month).

ARV drug class: number of participants on antiretroviral treatment with current or historic resistance to ≥ 1 drug in the specified ARV drug class (based on cumulative tests in BC, until the specified month).

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor.

NOTE: Testing for INSTI resistance in all DTP participants was not routinely performed in BC prior to 2022. As such, the proportion of Participants with INSTI resistance may be underestimated.

Never tested: number of participants on antiretroviral treatment who have never been tested for HIV drug resistance in BC.

%: ratio of n and total participants on antiretroviral treatment in the specified month.


Resistance interpretations were performed using Stanford University HIV Drug Resistance Database Algorithm (HIVdb) Version 10.1.

HIVdb scores ≥ 15 are classified as "resistant".





1.24 Participants by number of Antiretroviral Drug Classes with Resistance
February 2021 - February 2026





1.25 Participants by number of Antiretroviral Drug Classes with Resistance

MON-YYYY	Total Participants	0-Class (Wild Type) n %	1-Class n %	2-Class n %	3 or more Class n %	Never Tested n %
MAR-2024	7636	4111 53.8	1279 16.8	752 9.9	272 3.6	1222 16.0
APR-2024	7670	4123 53.8	1294 16.9	748 9.8	274 3.6	1231 16.1
MAY-2024	7687	4122 53.6	1294 16.8	752 9.8	273 3.6	1246 16.2
JUN-2024	7687	4125 53.7	1287 16.7	744 9.7	275 3.6	1256 16.3
JUL-2024	7718	4125 53.5	1294 16.8	750 9.7	278 3.6	1271 16.5
AUG-2024	7709	4127 53.5	1290 16.7	739 9.6	273 3.5	1280 16.6
SEP-2024	7697	4108 53.4	1291 16.8	740 9.6	273 3.6	1285 16.7
OCT-2024	7725	4138 53.6	1290 16.7	737 9.5	267 3.5	1293 16.7
NOV-2024	7703	4115 53.4	1286 16.7	737 9.6	263 3.4	1302 16.9
DEC-2024	7720	4124 53.4	1280 16.6	736 9.5	260 3.4	1320 17.1
JAN-2025	7739	4130 53.4	1284 16.6	736 9.5	253 3.3	1336 17.3
FEB-2025	7696	4095 53.2	1276 16.6	729 9.5	253 3.3	1343 17.5
MAR-2025	7689	4101 53.3	1278 16.6	719 9.4	252 3.3	1339 17.4
APR-2025	7719	4115 53.3	1277 16.5	723 9.4	250 3.2	1354 17.5
MAY-2025	7705	4101 53.2	1278 16.6	724 9.4	251 3.3	1351 17.5
JUN-2025	7713	4108 53.3	1271 16.5	720 9.3	246 3.2	1368 17.7
JUL-2025	7772	4134 53.2	1280 16.5	721 9.3	247 3.2	1390 17.9
AUG-2025	7761	4118 53.1	1279 16.5	723 9.3	247 3.2	1394 18.0
SEP-2025	7736	4096 53.0	1269 16.4	714 9.2	249 3.2	1408 18.2
OCT-2025	7774	4118 53.0	1279 16.5	717 9.2	244 3.1	1416 18.2
NOV-2025	7789	4129 53.0	1274 16.4	725 9.3	240 3.1	1421 18.2
DEC-2025	7833	4152 53.0	1272 16.2	722 9.2	244 3.1	1443 18.4
JAN-2026	7808	4130 52.9	1275 16.3	710 9.1	243 3.1	1450 18.6
FEB-2026	7789	4115 52.8	1282 16.5	708 9.1	244 3.1	1440 18.5

Total Participants: : number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.

Number of Antiretroviral (ARV) Drug Classes with Resistance considers resistance to N(t)RTI, NNRTI, PI, and INSTI drug classes only based on cumulative resistance tests for participants ever tested for HIV drug resistance in BC (until the specified month).

NOTE: Testing for INSTI resistance in all DTP participants was not routinely performed in BC prior to 2022. As such, the proportion of Participants with INSTI resistance may be underestimated.

Never tested: number of participants on antiretroviral treatment who have never been tested for HIV drug resistance in BC.

%: ratio of n and total participants on antiretroviral treatment in the specified month.

Resistance interpretations were performed using Stanford University HIV Drug Resistance Database Algorithm (HIVdb) Version 10.1.

HIVdb scores ≥ 15 are classified as "resistant".





2.1 Participants as of February 2026 by Year of HIV Treatment Program Initiation (1987 - 2026)

Program Start Year	Duration (years) Median	Naïve start	All	Male (Sex)	Female (Sex)	Age (Q1, Q3)		CD4 (cells/μL)			pVL Suppressed (<200 copies/mL) %		
								Tested (n)	Median	(Q1, Q3)	Tested (n)	Suppressed (n)	%
1987-1992	31	47	178	169	9	34	(30, 39)	86	540	(368, 740)	167	165	98.8
1993	30	121	122	108	14	34	(29, 39)	76	600	(418, 815)	114	113	99.1
1994	29	66	66	56	10	34	(29, 37)	46	635	(403, 833)	61	57	93.4
1995	29	123	124	107	17	34	(29, 39)	79	590	(415, 800)	111	108	97.3
1996	27	302	304	264	40	35	(30, 39)	172	625	(438, 865)	276	270	97.8
1997	25	257	263	239	24	34	(29, 38)	167	610	(390, 800)	233	230	98.7
1998	24	183	192	155	37	34	(30, 40)	123	590	(430, 780)	164	162	98.8
1999	24	164	165	127	38	36	(30, 42)	116	580	(388, 813)	150	148	98.7
2000	24	119	122	97	25	37	(33, 43)	81	710	(480, 860)	101	101	100.0
2001	24	118	120	96	24	37	(32, 44)	73	560	(400, 810)	102	101	99.0
2002	23	115	125	107	18	40	(31, 46)	78	560	(383, 763)	107	106	99.1
2003	22	140	150	129	21	39	(34, 45)	99	610	(420, 825)	136	133	97.8
2004	21	139	162	128	34	40	(34, 44)	108	680	(438, 865)	140	139	99.3
2005	20	176	193	152	41	41	(34, 47)	136	650	(460, 870)	177	173	97.7
2006	19	173	193	159	34	42	(33, 48)	131	600	(450, 860)	169	164	97.0
2007	18	232	250	213	37	41	(35, 46)	176	695	(468, 860)	228	226	99.1
2008	17	267	299	244	55	42	(34, 49)	218	650	(479, 875)	267	263	98.5
2009	16	294	327	265	62	41	(34, 47)	215	680	(470, 920)	291	286	98.3
2010	15	260	298	235	63	40	(32, 45)	205	680	(510, 860)	253	247	97.6
2011	14	304	347	285	62	41	(33, 48)	218	720	(533, 950)	303	297	98.0
2012	13	270	310	250	60	41	(32, 49)	204	700	(508, 920)	271	265	97.8
2013	12	245	291	229	62	40	(32, 48)	191	670	(485, 900)	249	241	96.8
2014	11	223	291	247	44	40	(31, 50)	191	740	(560, 965)	256	250	97.7
2015	10	192	272	233	39	40	(31, 50)	181	680	(500, 930)	245	237	96.7
2016	9	180	255	211	44	38	(32, 49)	173	680	(500, 960)	222	214	96.4
2017	9	150	218	187	31	36	(28, 45)	150	715	(530, 948)	191	183	95.8
2018	8	135	205	161	44	39	(31, 46)	140	830	(578, 1045)	179	173	96.7
2019	7	132	242	204	38	38	(29, 48)	175	700	(495, 915)	204	196	96.1
2020	6	97	192	144	48	37	(31, 48)	149	740	(570, 970)	159	153	96.2

Duration: cumulative years on antiretroviral treatment in BC program.

Age: age at first antiretroviral treatment dispensing in BC program.

CD4 and pVL refer to most recent test results in the last 12 months and last 6 months, respectively.





2.1 Active Participants as of February 2026 by Year of HIV Treatment Program Initiation (1987 - 2026) (cont.)

Program Start Year	Duration (years) Median	Naïve start	All	Male (Sex)	Female (Sex)	Age Median (Q1, Q3)	CD4 (cells/μL)			pVL Suppressed (<200 copies/mL) (n) %		
							Tested (n)	Median	(Q1, Q3)	Tested (n)		
2021	5	107	196	165	31	38 (30, 46)	138	650	(500, 840)	171	170	99.4
2022	4	105	264	218	46	39 (31, 47)	197	700	(510, 950)	228	224	98.3
2023	3	109	301	248	53	35 (30, 45)	236	650	(470, 830)	266	262	98.5
2024	2	135	331	266	65	36 (29, 46)	267	640	(460, 840)	300	290	96.7
2025	1	129	366	278	88	36 (30, 46)	337	600	(440, 800)	341	335	98.2
2026	0	21	55	45	10	38 (30, 47)	52	500	(225, 710)	51	31	60.8
Total:	13	5830	7789	6421	1368	38 (31, 46)	5384	660	(470, 870)	6883	6713	97.53

Duration: cumulative years on antiretroviral treatment in BC program.

Age: age at first antiretroviral treatment dispensing in BC program.

CD4 and pVL refer to most recent test results in the last 12 months and last 6 months, respectively.



2.2 HIV Viral Load (copies/mL) and CD4 (cells/μL) for Participants on Antiretroviral Treatment

MON-YYYY	Total Participants	Median # of Treatment days	CD4 (cells/μL)			pVL Suppressed (<200 copies/mL)		
			Tested (n)	Median	(Q1, Q3)	Tested (n)	(n)	%
MAR-2024	7636	790	5326	640	(450, 870)	6871	6677	97.2
APR-2024	7670	786	5310	640	(450, 870)	6842	6660	97.3
MAY-2024	7687	787	5318	650	(460, 880)	6896	6732	97.6
JUN-2024	7687	784	5306	650	(460, 870)	6921	6759	97.7
JUL-2024	7718	786	5335	650	(460, 870)	7009	6845	97.7
AUG-2024	7709	782	5312	650	(460, 873)	6937	6779	97.7
SEP-2024	7697	791	5304	650	(460, 870)	6904	6752	97.8
OCT-2024	7725	787	5314	650	(460, 870)	6898	6759	98.0
NOV-2024	7703	793	5308	650	(460, 880)	6875	6736	98.0
DEC-2024	7720	796	5326	650	(460, 880)	6913	6782	98.1
JAN-2025	7739	792	5331	650	(450, 880)	6882	6733	97.8
FEB-2025	7696	800	5304	650	(460, 880)	6871	6736	98.0
MAR-2025	7689	792	5287	650	(450, 875)	6812	6688	98.2
APR-2025	7719	779	5299	660	(460, 880)	6890	6743	97.9
MAY-2025	7705	787	5252	660	(460, 880)	6860	6707	97.8
JUN-2025	7713	785	5255	660	(460, 880)	6834	6678	97.7
JUL-2025	7772	773	5306	651	(460, 870)	6913	6773	98.0
AUG-2025	7761	780	5313	660	(460, 860)	6941	6796	97.9
SEP-2025	7736	792	5302	660	(460, 860)	6933	6788	97.9
OCT-2025	7774	785	5329	660	(470, 870)	6960	6817	98.0
NOV-2025	7789	774	5333	660	(470, 872)	6963	6821	98.0
DEC-2025	7833	771	5363	660	(470, 880)	6960	6811	97.9
JAN-2026	7808	774	5365	660	(470, 872)	6860	6706	97.8
FEB-2026	7789	774	5371	660	(470, 880)	6852	6689	97.6

Total participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.
Treatment days defined as number of consecutive days on antiretroviral treatment.
CD4 and pVL refer to most recent test results in the last 12 months and last 6 months, respectively.
% suppressed pVL is ratio of those tested.



2.3 BC-CfE HIV Treatment Program Enrolment

				----- Program Start -----			
MON-YYYY	Total Participants	Reported as Moved	Deceased	New	ART Naïve n %	ART Experienced n %	
MAR-2024	7636	3	12	36	13 36.1	23 63.9	
APR-2024	7670	1	17	46	20 43.5	26 56.5	
MAY-2024	7687	3	12	38	16 42.1	22 57.9	
JUN-2024	7687	2	5	44	23 52.3	21 47.7	
JUL-2024	7718	2	15	33	10 30.3	23 69.7	
AUG-2024	7709	9	13	34	15 44.1	19 55.9	
SEP-2024	7697	6	9	29	7 24.1	22 75.9	
OCT-2024	7725	7	8	41	15 36.6	26 63.4	
NOV-2024	7703	5	14	30	9 30.0	21 70.0	
DEC-2024	7720	0	15	32	10 31.3	22 68.8	
JAN-2025	7739	7	14	40	14 35.0	26 65.0	
FEB-2025	7696	3	10	28	9 32.1	19 67.9	
MAR-2025	7689	3	12	24	12 50.0	12 50.0	
APR-2025	7719	5	9	36	12 33.3	24 66.7	
MAY-2025	7705	4	18	34	17 50.0	17 50.0	
JUN-2025	7713	5	12	24	8 33.3	16 66.7	
JUL-2025	7772	5	8	42	8 19.1	34 81.0	
AUG-2025	7761	1	11	37	17 46.0	20 54.1	
SEP-2025	7736	5	6	37	13 35.1	24 64.9	
OCT-2025	7774	4	14	32	10 31.3	22 68.8	
NOV-2025	7789	4	7	41	19 46.3	22 53.7	
DEC-2025	7833	4	19	28	3 10.7	25 89.3	
JAN-2026	7808	1	13	26	9 34.6	17 65.4	
FEB-2026	7789	3	7	30	12 40.0	18 60.0	

ART: Antiretroviral Therapy.

Total Participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.

Reported as moved: number of participants moved out of BC program in the specified month.

Deceased: number of participants deceased in the specified month and were on ART in the past.

New Program Start: number of participants starting ART in the BC program for the first time in the specified month.

Program Start ART Naïve: number of new program starts who were never treated previously.

Program Start ART Experienced: number of new program starts who have been previously treated outside the BC Program.
(includes participants with unknown ART experience at enrolment).

%: ratio of n in the specified program start category and total new program start participants in the specified month.






3.1 Distribution of HIV Treatment Program Active Participants

February 2026

BY HEALTH SERVICE DELIVERY AREA






3.2 Distribution of HIV Treatment Program Active Participants

February 2026

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA






3.3 Distribution of HIV Treatment Program Active Participants

February 2026


FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA






3.4 Distribution of HIV Treatment Program Active Participants February 2026

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY LHA



*** Please refer to VIHA (432 and 434) on the next page






3.5 Distribution of HIV Treatment Program Active Participants

February 2026

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA

N = 1082






3.6 Distribution of HIV Treatment Program Active Participants

February 2026

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA





4.1 Demographic Profile of Program Participants

Health Authority	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
INTERIOR	626	8.0	56 (44-64)	545	700 (480-900)	518	503	97.1
FRASER	2184	28.0	53 (41-62)	1581	670 (480-880)	1940	1895	97.7
VANCOUVER COASTAL	3641	46.8	57 (44-64)	2606	660 (470-870)	3343	3272	97.9
VANCOUVER ISLAND	1082	13.9	58 (46-65)	414	610 (423-828)	897	871	97.1
NORTHERN	251	3.2	54 (44-63)	234	625 (403-888)	181	169	93.4
Total BC:	7789	100.0	56 (44-64)	5384	660 (470-870)	6883	6713	97.5

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	311	4.0	270	700 (530-940)	277	265	95.7
30 - 49	2500	32.1	1888	700 (510-923)	2176	2092	96.1
50 - 64	3202	41.1	2117	650 (450-860)	2836	2772	97.7
65+	1776	22.8	1109	610 (439-810)	1594	1584	99.4
Total BC:	7789	100.0	5384	660 (470-870)	6883	6713	97.5

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	6336	81.4	57 (44-65)	4196	654 (470-860)	5677	5557	97.9
Cis-women	1358	17.4	51 (43-59)	1110	680 (471-938)	1130	1085	96.0
Transmasculine	10	0.1	40 (32-47)	8	801 (593-1115)	9	8	88.9
Transfeminine	79	1.0	43 (33-54)	66	715 (576-983)	62	59	95.2
Total BC:	7789	100.0	56 (44-64)	5384	660 (470-870)	6883	6713	97.5

Program Duration	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
10 years or more	5193	66.7	60 (52-66)	3392	650 (460-860)	4598	4598	98.0
5 to 10 years	1110	14.3	45 (37-55)	786	720 (530-960)	954	954	96.5
<5 years	1486	19.1	38 (32-48)	1206	640 (460-840)	1331	1331	96.6
Total BC:	7789	100.0	56 (44-64)	5384	660 (470-870)	6883	6713	97.5

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total participants: number of participants on antiretroviral treatment in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested:: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Total BC: counts include participants on antiretroviral treatment in the specified month (includes unknown residence, not shown).

Gender Identity as reported by clinician.

Program Duration: cumulative years on antiretroviral treatment in BC program.





4.2 Demographic Profile of Program Participants in INTERIOR Health Authority

Health Service Delivery Area	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
EAST KOOTENAY	32	5.1	54 (39-60)	29	750 (600-990)	27	27	100.0
KOOTENAY BOUNDARY	51	8.2	60 (46-68)	45	740 (440-940)	45	43	95.6
OKANAGAN	364	58.2	56 (44-64)	328	650 (488-860)	305	296	97.1
THOMPSON/CARIBOO/SHUSWAP	179	28.6	55 (42-63)	143	770 (490-980)	141	137	97.2
Total HA:	626	100.0	56 (44-64)	545	700 (480-900)	518	503	97.1

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	25	4.0	23	820 (555-1040)	22	21	95.5
30 - 49	202	32.3	184	740 (540-933)	165	157	95.2
50 - 64	254	40.6	213	700 (460-900)	211	206	97.6
65+	145	23.2	125	560 (440-820)	120	119	99.2
Total HA:	626	100.0	545	700 (480-900)	518	503	97.1

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	493	78.8	57 (45-65)	429	660 (480-880)	418	407	97.4
Cis-women	126	20.1	51 (41-60)	111	780 (540-1035)	95	91	95.8
Gender Diverse	7	1.1	49 (39-54)	5	850 (620-1280)	5	5	100.0
Total HA:	626	100.0	56 (44-64)	545	700 (480-900)	518	503	97.1

HSDA Prescriber Practice Location	# of Prescribers currently prescribing Antiretroviral Treatment
EAST KOOTENAY	11
KOOTENAY BOUNDARY	15
OKANAGAN	50
THOMPSON/CARIBOO/SHUSWAP	29
Total HA:	105

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Gender Identity: as reported by clinician.

Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.





4.3 Distribution of Participants by Program Duration in INTERIOR Health Authority

HSDA	Program Duration	Total Participants (n) %	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %
EAST KOOTENAY	10 years or more	12 1.9	11	800 (705-915)	12	12 100.0
	5 to 10 years	11 1.8	9	880 (630-1080)	9	9 100.0
	<5 years	9 1.4	9	480 (460-750)	6	6 100.0
	Total HSDA:	32 5.1	29	750 (600-990)	27	27 100.0
KOOTENAY BOUNDARY	10 years or more	38 6.1	32	730 (423-940)	32	31 96.9
	5 to 10 years	7 1.1	7	780 (485-920)	7	6 85.7
	<5 years	6 1.0	6	770 (633-998)	6	6 100.0
	Total HSDA:	51 8.2	45	740 (440-940)	45	43 95.6
OKANAGAN	10 years or more	236 37.7	206	650 (480-860)	199	195 98.0
	5 to 10 years	46 7.4	45	700 (540-890)	41	40 97.6
	<5 years	82 13.1	77	610 (480-810)	65	61 93.9
	Total HSDA:	364 58.2	328	650 (488-860)	305	296 97.1
THOMPSON/CARIBOO/SHUSWAP	10 years or more	111 17.7	86	795 (493-1079)	86	83 96.5
	5 to 10 years	23 3.7	19	720 (510-860)	20	19 95.0
	<5 years	45 7.2	38	740 (480-918)	35	35 100.0
	Total HSDA:	179 28.6	143	770 (490-980)	141	137 97.2
Total HA:		626 100.0	545	700 (480-900)	518	503 97.1

	Program Duration	Total Participants (n) %	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %
	10 years or more	397 63.4	335	710 (480-910)	329	321 97.6
	5 to 10 years	87 13.9	80	725 (540-910)	77	74 96.1
	<5 years	142 22.7	130	650 (480-830)	112	108 96.4
Total HA:		626 100.0	545	700 (480-900)	518	503 97.1

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Program Duration: cumulative years on antiretroviral treatment in BC program.





4.4 Demographic Profile of Program Participants in FRASER Health Authority

Health Service Delivery Area	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
FRASER EAST	336	15.4	56 (42-63)	251	650 (460-845)	294	286	97.3
FRASER NORTH	897	41.1	53 (42-62)	654	700 (500-930)	794	782	98.5
FRASER SOUTH	951	43.5	53 (41-62)	676	660 (470-840)	852	827	97.1
Total HA:	2184	100.0	53 (41-62)	1581	670 (480-880)	1940	1895	97.7

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	135	6.2	121	700 (530-908)	126	120	95.2
30 - 49	774	35.4	610	700 (510-930)	690	673	97.5
50 - 64	858	39.3	571	650 (465-855)	753	732	97.2
65+	417	19.1	279	630 (440-830)	371	370	99.7
Total HA:	2184	100.0	1581	670 (480-880)	1940	1895	97.7

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	1643	75.2	55 (41-63)	1140	670 (476-853)	1478	1451	98.2
Cis-women	517	23.7	51 (42-59)	419	680 (500-958)	443	426	96.2
Gender Diverse	24	1.1	43 (32-54)	22	715 (598-903)	19	18	94.7
Total HA:	2184	100.0	53 (41-62)	1581	670 (480-880)	1940	1895	97.7

HSDA Prescriber Practice Location	# of Prescribers currently prescribing Antiretroviral Treatment
FRASER EAST	31
FRASER NORTH	37
FRASER SOUTH	43
Total HA:	111

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Gender Identity: as reported by clinician.

Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.





4.5 Distribution of Participants by Program Duration in FRASER Health Authority

HSDA	Program Duration	Total Participants (n)	%	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n)	%
FRASER EAST	10 years or more	212	9.7	147	650 (440-855)	183	180	98.4
	5 to 10 years	39	1.8	30	690 (564-945)	32	31	96.9
	<5 years	85	3.9	74	590 (453-808)	79	75	94.9
	Total HSDA:	336	15.4	251	650 (460-845)	294	286	97.3
FRASER NORTH	10 years or more	567	26.0	373	700 (490-920)	501	494	98.6
	5 to 10 years	135	6.2	111	790 (550-970)	116	114	98.3
	<5 years	195	8.9	170	640 (460-915)	177	174	98.3
	Total HSDA:	897	41.1	654	700 (500-930)	794	782	98.5
FRASER SOUTH	10 years or more	552	25.3	381	655 (470-830)	483	468	96.9
	5 to 10 years	140	6.4	89	710 (486-896)	124	119	96.0
	<5 years	259	11.9	206	650 (444-809)	245	240	98.0
	Total HSDA:	951	43.5	676	660 (470-840)	852	827	97.1
Total HA:		2184	100.0	1581	670 (480-880)	1940	1895	97.7

	Program Duration	Total Participants (n)	%	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n)	%
	10 years or more	1331	60.9	901	670 (480-877)	1167	1142	97.9
	5 to 10 years	314	14.4	230	736 (530-950)	272	264	97.1
	<5 years	539	24.7	450	640 (450-840)	501	489	97.6
Total HA:		2184	100.0	1581	670 (480-880)	1940	1895	97.7

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Program Duration: cumulative years on antiretroviral treatment in BC program.





4.6 Demographic Profile of Program Participants in VANCOUVER COASTAL Health Authority

Health Service Delivery Area	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
NORTH SHORE/COAST GARIBALDI	290	8.0	60 (49-67)	220	690 (530-940)	251	249	99.2
RICHMOND	162	4.5	54 (41-62)	141	610 (500-840)	154	152	98.7
VANCOUVER	3189	87.6	56 (44-64)	2245	660 (470-870)	2938	2871	97.7
Total HA:	3641	100.0	57 (44-64)	2606	660 (470-870)	3343	3272	97.9

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	102	2.8	90	700 (598-920)	91	90	98.9
30 - 49	1144	31.4	878	700 (530-940)	1034	995	96.2
50 - 64	1519	41.7	1071	650 (440-865)	1399	1373	98.1
65+	876	24.1	567	610 (440-805)	819	814	99.4
Total HA:	3641	100.0	2606	660 (470-870)	3343	3272	97.9

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	3140	86.2	58 (45-65)	2148	660 (470-860)	2912	2858	98.2
Cis-women	448	12.3	52 (44-60)	413	680 (460-900)	385	372	96.6
Gender Diverse	53	1.5	43 (32-53)	45	700 (550-990)	46	42	91.3
Total HA:	3641	100.0	57 (44-64)	2606	660 (470-870)	3343	3272	97.9

HSDA Prescriber Practice Location	# of Prescribers currently prescribing Antiretroviral Treatment
NORTH SHORE/COAST GARIBALDI	40
RICHMOND	8
VANCOUVER	204
Total HA:	252

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Gender Identity: as reported by clinician.

Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.





4.7 Distribution of Participants by Program Duration in VANCOUVER COASTAL Health Authority

HSDA	Program Duration	Total Participants (n)	%	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n)	%
NORTH SHORE/COAST GARIBALDI	10 years or more	213	5.9	154	685 (530-918)	187	186	99.5
	5 to 10 years	37	1.0	27	760 (575-1015)	28	28	100.0
	<5 years	40	1.1	39	670 (485-930)	36	35	97.2
	Total HSDA:	290	8.0	220	690 (530-940)	251	249	99.2
RICHMOND	10 years or more	88	2.4	71	630 (525-860)	83	82	98.8
	5 to 10 years	29	0.8	26	620 (528-863)	29	28	96.6
	<5 years	45	1.2	44	585 (458-810)	42	42	100.0
	Total HSDA:	162	4.5	141	610 (500-840)	154	152	98.7
VANCOUVER	10 years or more	2288	62.8	1519	650 (450-850)	2115	2076	98.2
	5 to 10 years	437	12.0	334	730 (540-990)	390	375	96.2
	<5 years	464	12.7	392	660 (480-840)	433	420	97.0
	Total HSDA:	3189	87.6	2245	660 (470-870)	2938	2871	97.7
Total HA:		3641	100.0	2606	660 (470-870)	3343	3272	97.9

	Program Duration	Total Participants (n)	%	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n)	%
	10 years or more	2589	71.1	1744	650 (460-860)	2385	2344	98.3
	5 to 10 years	503	13.8	387	730 (540-980)	447	431	96.4
	<5 years	549	15.1	475	660 (480-840)	511	497	97.3
Total HA:		3641	100.0	2606	660 (470-870)	3343	3272	97.9

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Program Duration: cumulative years on antiretroviral treatment in BC program.





4.8 Demographic Profile of Program Participants in VANCOUVER ISLAND Health Authority

Health Service Delivery Area	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
CENTRAL VANCOUVER ISLAND	317	29.3	58 (48-66)	162	560 (360-828)	270	259	95.9
NORTH VANCOUVER ISLAND	107	9.9	61 (48-66)	53	650 (470-850)	82	78	95.1
SOUTH VANCOUVER ISLAND	658	60.8	57 (45-65)	199	630 (450-810)	545	534	98.0
Total HA:	1082	100.0	58 (46-65)	414	610 (423-828)	897	871	97.1

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	36	3.3	23	620 (400-960)	28	26	92.9
30 - 49	293	27.1	137	610 (410-820)	232	221	95.3
50 - 64	464	42.9	162	615 (460-850)	389	379	97.4
65+	289	26.7	92	570 (398-740)	248	245	98.8
Total HA:	1082	100.0	414	610 (423-828)	897	871	97.1

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	890	82.3	59 (47-66)	321	600 (430-810)	743	722	97.2
Cis-women	183	16.9	54 (45-61)	89	640 (430-900)	148	143	96.6
Gender Diverse	*	*	*	*	*	*	*	*
Total HA:	1082	100.0	58 (46-65)	414	610 (423-828)	897	871	97.1

HSDA Prescriber Practice Location	# of Prescribers currently prescribing Antiretroviral Treatment
CENTRAL VANCOUVER ISLAND	71
NORTH VANCOUVER ISLAND	34
SOUTH VANCOUVER ISLAND	51
Total HA:	156

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Gender Identity: as reported by clinician.

Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.





4.9 Distribution of Participants by Program Duration in VANCOUVER ISLAND Health Authority

HSDA	Program Duration	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
CENTRAL VANCOUVER ISLAND	10 years or more	220	20.3	106	610 (440-858)	188	185	98.4
	5 to 10 years	50	4.6	22	630 (445-988)	40	38	95.0
	<5 years	47	4.3	34	360 (253-628)	42	36	85.7
	Total HSDA:	317	29.3	162	560 (360-828)	270	259	95.9
NORTH VANCOUVER ISLAND	10 years or more	81	7.5	36	590 (455-793)	64	61	95.3
	5 to 10 years	12	1.1	8	845 (630-890)	9	9	100.0
	<5 years	14	1.3	9	720 (620-970)	9	8	88.9
	Total HSDA:	107	9.9	53	650 (470-850)	82	78	95.1
SOUTH VANCOUVER ISLAND	10 years or more	407	37.6	115	640 (455-805)	343	337	98.3
	5 to 10 years	112	10.4	29	650 (450-860)	87	85	97.7
	<5 years	139	12.9	55	560 (445-770)	115	112	97.4
	Total HSDA:	658	60.8	199	630 (450-810)	545	534	98.0
Total HA:		1082	100.0	414	610 (423-828)	897	871	97.1

	Program Duration	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
	10 years or more	708	65.4	257	620 (440-810)	595	583	98.0
	5 to 10 years	174	16.1	59	660 (460-865)	136	132	97.1
	<5 years	200	18.5	98	550 (345-760)	166	156	94.0
Total HA:		1082	100.0	414	610 (423-828)	897	871	97.1

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Program Duration: cumulative years on antiretroviral treatment in BC program.





4.10 Demographic Profile of Program Participants in NORTHERN Health Authority

Health Service Delivery Area	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
NORTH EAST	34	13.6	50 (39-62)	31	630 (495-875)	24	21	87.5
NORTH WEST	62	24.7	54 (46-61)	56	650 (455-898)	49	46	93.9
NORTHERN INTERIOR	155	61.8	54 (44-63)	147	610 (370-905)	108	102	94.4
Total HA:	251	100.0	54 (44-63)	234	625 (403-888)	181	169	93.4

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	13	5.2	13	840 (480-1320)	10	8	80.0
30 - 49	83	33.1	76	645 (438-1000)	52	44	84.6
50 - 64	106	42.2	99	600 (415-875)	83	81	97.6
65+	49	19.5	46	530 (343-768)	36	36	100.0
Total HA:	251	100.0	234	625 (403-888)	181	169	93.4

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	167	66.5	55 (45-63)	156	640 (400-880)	124	118	95.2
Cis-women	82	32.7	50 (42-61)	76	600 (413-930)	57	51	89.5
Gender Diverse	*	*	*	*	*	*	*	*
Total HA:	251	100.0	54 (44-63)	234	625 (403-888)	181	169	93.4

HSDA Prescriber Practice Location	# of Prescribers currently prescribing Antiretroviral Treatment
NORTH EAST	2
NORTH WEST	14
NORTHERN INTERIOR	18
Total HA:	34

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Gender Identity: as reported by clinician.

Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.





4.11 Distribution of Participants by Program Duration in NORTHERN Health Authority

HSDA	Program Duration	Total Participants (n) %	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %
NORTH EAST	10 years or more	* *	*	*	*	* *
	5 to 10 years	* *	*	*	*	* *
	<5 years	* *	*	*	*	* *
	Total HSDA:	<5 N/A	<5	N/A	<5	<5 N/A
NORTH WEST	10 years or more	42 16.7	37	650 (440-960)	33	31 93.9
	5 to 10 years	8 3.2	7	700 (580-790)	5	5 100.0
	<5 years	12 4.8	12	565 (455-890)	11	10 90.9
	Total HSDA:	62 24.7	56	650 (455-898)	49	46 93.9
NORTHERN INTERIOR	10 years or more	109 43.4	103	590 (335-935)	76	72 94.7
	5 to 10 years	22 8.8	21	780 (380-990)	15	14 93.3
	<5 years	24 9.6	23	620 (510-795)	17	16 94.1
	Total HSDA:	155 61.8	147	610 (370-905)	108	102 94.4
Total HA:		251 100.0	234	625 (403-888)	181	169 93.4

	Program Duration	Total Participants (n) %	# CD4 Tested	Median CD4 (Q1 - Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %
	10 years or more	167 66.5	154	610 (400-950)	121	115 95.0
	5 to 10 years	32 12.8	30	690 (383-880)	22	20 90.9
	<5 years	52 20.7	50	625 (473-838)	38	34 89.5
Total HA:		251 100.0	234	625 (403-888)	181	169 93.4

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Program Duration: cumulative years on antiretroviral treatment in BC program.





4.12 Demographic Profile of Program Participants with Clinician-reported Indigenous Status

Health Authority	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
INTERIOR	48	6.9	55 (47-60)	43	540 (360-800)	44	38	86.4
FRASER	114	16.3	56 (46-62)	85	570 (380-720)	96	89	92.7
VANCOUVER COASTAL	352	50.4	55 (46-61)	315	520 (330-760)	316	301	95.3
VANCOUVER ISLAND	90	12.9	56 (46-63)	48	535 (423-728)	69	66	95.7
NORTHERN	94	13.5	52 (44-61)	88	500 (340-740)	70	61	87.1
Total BC:	698	100.0	55 (46-62)	579	540 (340-750)	595	555	93.3

Age Group	Total Participants (n) %		# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
0 - 29	18	2.6	16	630 (475-898)	16	14	87.5
30 - 49	226	32.4	198	559 (373-770)	180	157	87.2
50 - 64	350	50.1	287	510 (320-759)	310	296	95.5
65+	104	14.9	78	535 (340-718)	89	88	98.9
Total BC:	698	100.0	579	540 (340-750)	595	555	93.3

Gender Identity	Total Participants (n) %		Median Age (Q1-Q3)	# CD4 Tested	Median CD4 (Q1-Q3)	# pVL Tested	Suppressed pVL (<200 copies/mL) (n) %	
Cis-men	428	61.3	57 (47-63)	340	520 (330-723)	372	356	95.7
Cis-women	254	36.4	52 (43-59)	226	560 (343-780)	210	188	89.5
Gender Diverse	16	2.3	52 (46-55)	13	590 (480-850)	13	11	84.6
Total BC:	698	100.0	55 (46-62)	579	540 (340-750)	595	555	93.3

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Total Participants: participants with clinician-reported Indigenous Status, on ART in BC program in the specified month based on dispensing data.

% (Total Participants): ratio of n and total participants on antiretroviral treatment in the specified month.

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL).

% (Suppressed pVL): ratio of those tested.

Gender Identity: as reported by clinician.

Gender Diverse may include transmasculine, transfeminine, non-binary and other clinician reported and unreported gender identities.





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment
Program provided in-part by:

